Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$141.21 USD

141.21
5,697,169

-1.85 (-1.29%)

Updated Sep 26, 2022 04:03 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.63%
2Buy18.00%
3Hold9.55%
4Sell5.25%
5Strong Sell2.32%
S&P50010.82%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 251)

Industry: Large Cap Pharmaceuticals

Trades from $1

Zacks News

North Chicago, IL-based AbbVie has become one of the top-most pharma companies after it acquired Botox maker Allergan in a cash-and-stock deal for $63 billion in May 2020. The deal is expected to transform AbbVie’s portfolio and lower its dependence on Humira, its flagship product, which has already lost patent protection in Europe and is due to face biosimilar competition in the United States in 2023. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) position it well for long-term growth.

AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know

AbbVie (ABBV) closed at $141.21 in the latest trading session, marking a -1.29% move from the prior day.

Is Trending Stock AbbVie Inc. (ABBV) a Buy Now?

AbbVie (ABBV) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

AbbVie (ABBV) Gets CHMP Nod for Skyrizi in a Third Indication

The CHMP recommends authorizing AbbVie's (SNY) Skyrizi as a treatment for Crohn's disease. The drug is approved for treating plaque psoriasis and psoriatic arthritis indications.

The Zacks Analyst Blog Highlights Apple, Amazon, AbbVie, Philip Morris International and BlackRock

Apple, Amazon, AbbVie, Philip Morris International and BlackRock are included in this Analyst Blog.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $142.66, moving -0.97% from the previous trading session.

Mark Vickery headshot

Top Analyst Reports for Apple, Amazon.com & AbbVie

Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), Amazon.com, Inc. (AMZN) and AbbVie Inc. (ABBV).

The Zacks Analyst Blog Highlights AbbVie, Novartis, Merck and AstraZeneca

AbbVie, Novartis, Merck and AstraZeneca are included in this Analyst Blog.

Kinjel Shah headshot

4 Large Drug Stocks to Watch as Fundamentals Stay Strong

Drug/biotech companies are likely to see significant advances in innovation in 2023. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novartis (NVS), Merck (MRK) and AstraZeneca (AZN) are worth retaining in your portfolio.

AbbVie (ABBV) Gains But Lags Market: What You Should Know

AbbVie (ABBV) closed the most recent trading day at $142.24, moving +0.58% from the previous trading session.

Revance (RVNC) Gets FDA Nod for Anti-Wrinkle Product, Stock Up

FDA approves Revance Therapeutics' (RVNC) Daxxify as a long-acting neuromodulator with a strong label that includes 36-week efficacy data from the SAKURA clinical program.

Is Most-Watched Stock AbbVie Inc. (ABBV) Worth Betting on Now?

Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

SpringWorks (SWTX), GSK Expand Deal to Treat Multiple Myeloma

Per the partnership, SpringWorks Therapeutics (SWTX) will supply nirogacestat to GSK's (GSK) development program for its multiple myeloma drug, Blenrep.

Ironwood's (IRWD) Functional Constipation Study in Kids Succeeds

Ironwood (IRWD) reports positive top-line data from a late-stage study evaluating Linzess (linaclotide) for functional constipation in pediatric patients aged six to 17 years.

Curis (CRIS) Gets FDA Nod to Partly Resume Leukemia Study

The FDA allows Curis (CRIS) to resume enrollment of additional patients in the monotherapy phase of the TakeAim Leukemia study on emavusertib in patients will acute myeloid leukemia and myelodysplastic syndrome. Shares down.

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

    AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

    Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.

    The Zacks Analyst Blog Highlights Novartis, J&J, AbbVie, Merck and Pfizer

    Novartis, J&J, AbbVie, Merck and Pfizer are part of The Zacks top Analyst Blog.

    Kinjel Shah headshot

    Pharma Stock Roundup: NVS to Spin Off Sandoz; JNJ, MRK, ABBV's FDA Updates

    Novartis (NVS) plans to spin off its generics division, Sandoz. The FDA approves J&J (JNJ) and AbbVie's (ABBV) Imbruvica for pediatric indication cGVHD.

    Annovis Bio (ANVS) Begins Dosing in Phase III Parkinson's Study

    Annovis Bio (ANVS) doses first patient in the phase III study evaluating buntanetap in early Parkinson's Disease. Stock surges.

    AbbVie (ABBV), J&J's Imbruvica Gets FDA Nod for cGVHD in Kids

    AbbVie (ABBV) and J&J's (JNJ) Imbruvica gets FDA nod for label expansion to treat pediatric patients with chronic graft versus host disease. It is also the first BTK inhibitor approved for use in pediatric patients

    Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study

    Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.

    Curis (CRIS) Lymphoma Study's Clinical Hold Lifted, Shares Gain

    The FDA lifts partial clinical hold on Curis' (CRIS) phase I/II TakeAim lymphoma study investigating emavusertib in patients with B-cell malignancies. Shares surge.

    The Zacks Analyst Blog Highlights JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar

    JPMorgan Chase, AbbVie, Abbott Laboratories, Intuit and Caterpillar are included in this Analyst Blog.